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Objective: Over 23 million people are affected by asthma in the United States and 262 million 
individuals globally. Asthma, if poorly controlled, is associated with significant morbidity as 
well as increased risk for mortality. Several complex inflammatory pathways and processes are 
involved leading to an increase in immune cell activation. Curcumin, the active constituent found 
in turmeric, has been studied in numerous in-vivo and in-vitro studies to generate anti-
inflammatory effects in pulmonary diseases. More recently, an increase in clinical data has 
become available, and since the most recent review assessing the role of curcumin in pulmonary 
disorders, additional clinical trials have been published. We provide the first meta-analysis 
evaluating the efficacy of curcumin supplementation in asthma. 
 
Methods: We searched PubMed and Google Scholar for eligible studies up to June 30, 2021, 
using medical subject headings and keywords for asthma. Any clinical trial design, conducted in 
humans, assessing the efficacy of curcumin on asthma related symptoms and lung functioning 
were included. Two authors, using predefined criteria, independently screened, extracted data, 
and assessed risk of bias from included studies using predefined criteria. Random effects meta-
analysis was performed for each outcome, with effect size reported as mean difference (MD) or 
as a standardized mean difference.  
 
Results: 1,216 studies were screened, 8 included for review (n = 509) and adequate data from 3 
trials (n = 203) included for meta-analysis. Most participants were of female sex (52.2%) and the 
mean age (SD) of participants was 39.23 (14.7) years. The forced expiratory volume in one 
second (FEV1%) improved with curcumin supplementation (3 studies; pooled MD = 3.70 (1.00, 
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6.41), p= 0.007, I2=0%) compared to control. Efficacy of curcumin supplementation on asthma 
symptoms more generally were discordant and safety data was only reported in two trials. 
 
Conclusions: Supplementation with curcumin may provide small improvements in FEV1%, 
however conclusions are limited by the small number of studies and sample sizes, poor 
methodological quality, inconsistent reporting of asthma related outcomes and high risk of bias 
of included studies. Additional, high-quality, human trials are needed to assess the efficacy of 













Asthma is a prevalent immune mediated disorder often associated with sensitivities to 
airborne environmental irritants. Globally, the World Health Organization (WHO) estimates 262 
million people have asthma and an estimated 25 million individuals in the United States, 
according to The Center for Disease Control and Prevention (CDC).1,2 Asthma is more prevalent 
amongst females and direct and indirect costs result in an annual expenditure between $56 to $82 
billion.2-4 
 Asthma’s pathophysiology is complex, involving several mechanistic pathways 
ultimately leading to the interaction of Nuclear Factor kappa-light-chain-enhancer of activated 
B-cells (NFκB) cross-linking with IgE. This cross-linking activates mast cells, basophils and 
eosinophils causing a release of histamines and other inflammatory mediators such as c-reactive 
protein (CRP), tumor necrosis factor-α (TNF-α) and, interleukins.5-7 These inflammatory 
mediators result in the constriction of airways producing clinical symptoms of asthma such as 
wheezing, breathlessness and frequent nighttime awakenings due to coughing.5 
The Global Initiative for Asthma (GINA) utilizes clinical symptoms in addition to 
spirometry testing to diagnose asthma and categorizes asthma by clinical phenotype with   
further subclassification based on severity (intermittent, mild, moderate, and severe).8 Suspicion 
for asthma can be confirmed by spirometry when the forced expiratory volume of air in one 
second (FEV1) is able to increase by at least 12% following the use of a short acting 
bronchodilating agent.8 The use of various bronchodilators, corticosteroids, anti-inflammatory, 
and/or biologic agents are routinely used as standard of care therapies for asthma, however, the 
use of complementary and integrative health (CIH) practices for asthma are also highly 
prevalent. An estimated 58.5% of adults in the U.S. use CIH practices for asthma, and although 
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data is sparse and varies by region, an estimated 27-76% of children with asthma also use some 
form of CIH.9,10 In U.S. based adults, herbal therapies comprised 21% of the natural products 
used for asthma, however, which herbal therapies are used specifically, is less certain.9 
Curcuma longa (turmeric), a plant species native to tropical South Asia, has been 
traditionally used as a medicinal herb for centuries in Ayurvedic and Chinese medicine.5,11 Its 
rhizome is a common ingredient in many types of dishes such as curry, and Ng et al., suggested 
regular consumption of curry-based meals were independently associated with improvements in 
asthma after adjusting for gender, age, height, housing status, smoking, occupational exposure, 
asthma/COPD history, dietary, and other dietary supplemental intake.12 The main constituent of 
Curcuma longa, curcumin, has also routinely demonstrated anti-inflammatory effects in a variety 
of health-related conditions.11,13,14 Recently, there has been an increasing amount of literature 
available on the potential therapeutic role of curcumin for the treatment of pulmonary disorders 
including asthma, however, reviews of the literature are largely limited to investigating its effects 
from in-vivo or in-vitro models.5,11 
Despite a recent 2017 comprehensive review assessing curcumin in pulmonary diseases, 
only two clinical trials assessing its role in asthma were included, provided conflicting results, 
and failed to include a 2010 randomized controlled trial.5,15 Given several clinical trials have 
been published since then, the purpose of this study is to systematically review the literature and 
provide the most up to date clinical evidence assessing the efficacy and safety of curcumin 
supplementation in asthmatics. To our knowledge, we are also the first authors to meta-analyze 






This study followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.16 A protocol of this review was not prospectively registered.  
 
Eligibility for inclusion:  
Patients:  
Review authors included all randomized controlled trials (RCTs) and quasi-RCTs 
assessing the efficacy of curcumin supplementation for asthma. Studies were included if asthma 
participants were diagnosed by a physician or met asthma diagnostic criteria by spirometry at 
study entry. Primary study authors were contacted by email for any missing or unclear 
information, however, studies were not excluded from narrative review if no response was 
obtained, given the limited number of publications available. Conference abstracts of clinical 
data was also included if sufficient data could be obtained. No restrictions were placed on age, 
sex, or weight of participants; type of asthma; setting; or language of publication provided a 
publication written in any language other than English could be sufficiently translated via 
Google Translate.  
 
Intervention:  
No restrictions were placed on curcumin supplementation administered in any form 
(capsule, powder, etc.) route (oral, parenteral, etc.), dose, or length of time. Given curcumin is 
the main active constituent of turmeric, studies utilizing turmeric in any form, route, dose, or 




Studies were eligible for inclusion if the intervention was compared to placebo, standard 
of care for asthma, or an active comparator.  
 
Outcomes:  
Studies were included if they measured at least one of the following outcome measures of 
interest: (1) asthma symptoms defined as the number of asthma exacerbations per week, 
nocturnal symptoms or awakenings due to asthma per week, frequency of rescue medication(s) 
used per week, number of daytime symptoms per week, and the total score on the Asthma 
Control Test (ACT) or Asthma Quality of Life Questionnaire (AQLQ); (2) lung functioning 
assessed by spirometry or peak flowmetry including the forced expiratory volume in one second 
(FEV1), forced vital capacity (FVC), ratio of FEV1 to FVC (FEV1/FVC), or the peak expiratory 
flow rate (PEFR); and (3) safety and tolerability of curcumin supplementation.  
 
Exclusion criteria:  
Studies were excluded if they: (1). were conducted in animals; (2). were in-vitro, prospective or 
retrospective cohorts, cross-sectional, case-series, or case-control study designs; (3). unable to be 
translated via Google Translate; (4). included participants with other respiratory conditions 
(COPD, restrictive lung disease, pneumonia etc.); (5). did not report on any outcomes of interest 




Search strategy:  
We searched PubMed and the first 1,000 results in Google Scholar from inception until 
June 2021 with the assistance of a university librarian trained in literature searches. Reference 
lists of included studies as well as previous reviews were hand searched. ClinicalTrials.gov and 
the International Clinical Trials Registry Platform Search Portal (ICTRP) were searched for 
ongoing or completed trials. The International Prospective Register of Systematic Reviews 
(PROSPERO) was searched for similar ongoing or recently completed systematic reviews 
addressing our study objectives. The search strategy can be accessed in the accompanying 
appendix at the end of the manuscript (appendix 1).  
 
Data Collection:  
Authors used Mendeley Desktop for literature search results and management of 
screening results. Studies meeting inclusion criteria were entered into Review Manager 
(RevMan) version 5.3 software to create risk of bias summaries, extract data from studies for 
meta-analysis, and present results in forest plots if appropriate.17 Both authors screened titles and 
abstracts independently, with disagreements settled via consensus between study authors. TG 
and AS conducted all data extraction and data was inputted into RevMan5.3. Any disagreement 
in extraction of data was settled via consensus. Data items collected can be seen in table 1. 
 
Risk of Bias Assessment:  
The Cochrane Collaboration’s Risk of Bias tool was used to evaluate the risk of bias in 
seven selected domains included: 1) random sequence generation, 2) allocation concealment, 3) 
blinding of participants and personnel, 4) blinding of outcome assessment, 5) incomplete 
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outcome data, 6) selective reporting, and 7) other biases.18 Each domain of bias was rated as low 
risk, unclear risk, or high risk of bias, respectively.  
 
Data Analysis:  
Due to the heterogeneity across study methodologies in addition to adequate data only 
available for assessing FEV1%, a random-effects meta-analysis was used to derive pooled 
weighted mean differences (WMD) with 95% confidence intervals (95% CI) using an inverse 
variance model of post-intervention effects.19 Heterogeneity across studies was calculated using 
the I2 statistic to assess heterogeneity between studies for study results.  We considered an I2 of 
0-24% as low heterogeneity, 25-49% as mild heterogeneity, 50-74% as high heterogeneity, and 
I2>75% considered as extensive heterogeneity.20 Given the lack of available studies for meta-
analysis, heterogeneity was not further explored by sensitivity analyses or sub-group analyses. 
Furthermore, evidence for potential publication bias was not attempted given the paucity of data 
available.   
 
Results: 
1,216 studies were identified through database and registry search strategy; 8 were 
eligible for inclusion in the systematic review with 3 providing adequate data for meta-analysis 
(Figure 1). Two studies were identified in ClinicalTrials.gov of which, one was published and 
identified in our PubMed search, with another study currently in progress (NCT04353310). Two 
additional ongoing studies were found in the ICTRP (IRCT20191221045837N3) and 
IRCT20161226031584N2). No relevant reviews were identified in PROSPERO.  
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Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. 
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Study characteristics: 
Study characteristics can be seen in Table 1. Two studies were conducted in Bosnia and 
Herzegovina,23,27 with one study each conducted in Egypt15, India26 Indonesia24, Iraq21, Brazil22, 
and the United States of America.25 Four studies compared curcumin to placebo15, 22, 25, 27, five 
compared curcumin  added to standard of care/active comparator vs standard of care/active 
comparator alone21, 23, 24, 26, 27, , two compared combination products containing curcumin to 
placebo or control15,21, and one trial compared powdered whole turmeric to identical placebo.22 In 
one study, data was only available by conference abstract, however, despite attempts at 
contacting authors, further information was unable to be obtained.23 The longest trial length was 
six-months22, with the shortest trial performed by Sutedijo et al, however, the exact length of the 
study was unclear.24  
 
Participant characteristics: 
There was a total of n = 509 participants across 8 studies (n=203 included in meta-
analysis) with a total of n = 240 in curcumin, n = 269 in control groups. Mean age (39.23 ± 14.7) 
of participants was reported in six studies, and 52.2% of study participants from six studies were 
female.  
 
Risk of Bias in individual studies: 
Summary of the risk of bias of included studies can be seen in Figure 2. One reference 
was judged as having unclear risk of bias as it was published as a conference abstract only, 
without an ability to contact abstract authors.23 Due to significant drop out after randomization, 
one study was assessed as having high risk of bias for incomplete outcome data, and another 
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Effect of curcumin on lung functioning: 
Adequate data for meta-analysis was only available for FEV1%, which improved with 
the addition of curcumin relative to control (3 studies: MD = 3.7% (1.0, 6.4), P = 0.007, I2 = 
0%). Data was available from one abstract, however, reported mean FEV1% between groups 
were not incorporated into meta-analysis as it was unclear if standard deviations were reported 
despite efforts made in contacting corresponding authors.23 Manarin et al., reported FEV1% 
graphically with medians and interquartile ranges, with no statistically significant difference 
between groups and was not incorporated into meta-analysis.22 Three studies (n=115) reported 
FEV1 in liters however, heterogeneity in reporting FEV1 measures limited pooling results into 
meta-analysis.21, 25, 26 Of these three studies, two found no statistically significant difference 
between groups.21,25 
Figure 2: Risk of bias summary: review 
authors' judgements about each risk of bias 




Peak expiratory flow rate  
Two studies (n = 93) evaluated effects of curcumin supplementation on peak expiratory 
flow rate; one as a RCT and the other as a quasi-experimental study in hospitalized asthmatic 
patients.15,24 Neither study found statistically significant differences between groups. 
 
Effect of curcumin on asthma symptoms: 
A lack of adequate data was reported to assess the effects of curcumin on asthma 
symptoms and results are described narratively. Improvements in asthma symptoms are 
conflicting; four studies (n = 347) were able to identify statistically significant improvements in 
asthma symptoms compared to controls,15, 22, 23, 27,with two studies (n = 75) finding no 
statistically significant improvements in asthma symptoms.25, 26 Asthma Control Test (ACT) 
scores were reported in two studies25, 27 (n=165) with conflicting results, and one abstract which 
found statistically significant improvements in the curcumin group compared to control.23 
 
Daytime symptoms 
Two studies (n=123) reported the effects of curcumin supplementation for daytime 
symptoms with conflicting results.15, 26 One study found a median of four fewer daytime 
Figure 3: Forest plot for primary outcome comparing curcumin supplementation to controls. CI, confidence interval 
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symptoms per week compared to placebo group (p<0.001)15, however, another found no 
differences between curcumin or control groups in any symptom including difficulty breathing, 
wheezing, cough, or chest tightness.26 
 
Nocturnal symptoms 
Two studies (n = 97) reported statistically significant reductions in nocturnal symptoms 
relative to control groups.15,22 Houssen et al., found a median reduction of two nocturnal 
awakenings per week compared to placebo (p<0.001),15 with another study finding no 
statistically significant differences between groups in reductions of nighttime symptoms.26 
 
Need for rescue inhaler 
Two studies (n = 97) reported statistically significant reductions in the need for rescue 
inhalers with the addition of curcumin relative to control15, 22, with one able to demonstrate a 
median reduction of two fewer days per week of rescue inhaler use compared to placebo 
(p<0.001).15 In the trial by Manarain et al, at baseline, over 20% of participants in the curcumin 
group required daily use of rescue inhaler with none requiring daily rescue medication after six-
months.22 At baseline, greater than 25% of control participants required daily use of rescue 
inhaler, and greater than 20% still required daily use of rescue inhaler at six-months.22 Two 
studies (n=75)  did not find any differences between groups in reliance on rescue inhalers, 
however, results were not readily available from one study despite attempts at contacting the 
authors.25,26 
 
Frequency of acute exacerbations  
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The number of exacerbations per week was only recorded by one study which found a 
median reduction of two exacerbations per week relative to control group (p<0.001).15 
 
Safety of Curcumin: 
Only two trials (n = 94) reported safety data with neither study revealing increased risk of 
harm with curcumin.22,26 
 
Discussion: 
Clinical data from eight studies (n = 509) were included in this review, providing some 
evidence of an effect on lung functioning as seen by a 4% increase in FEV1, as well as overall 
improvements in asthma symptoms. These improvements build upon prior evidence highlighting 
curcumin’s ability to inhibit inflammatory cytokines and upregulate anti-inflammatory immune 
activation leading to a reduction of airway hyperresponsiveness and relaxation of smooth muscle 
cells within the bronchopulmonary system.5, 7, 28 
Heterogeneity in how asthma symptoms were reported by included studies prevented 
pooling of results to provide a quantitative estimate for how much of an effect curcumin 
supplementation can provide for specific asthma related symptoms (e.g., daytime symptoms, 
nocturnal symptoms, reliance on rescue inhaler). Despite most studies suggesting improvements 
in asthma related symptoms, the overall methodological quality of included studies was low, 
with only two double blinded RCTs available, and most studies at unclear or high risk of bias. As 
such, readers should interpret our findings with caution and three additional on-going clinical 
trials (NCT04353310, IRCT20191221045837N3 and IRCT20161226031584N2) are likely to 




This is the first review the study authors are aware of that provides a meta-analysis of 
clinical data evaluating the effects of curcumin supplementation in asthma. We have included the 
largest number of studies conducted in humans with asthma compared to previously conducted 
reviews which were limited to only two studies.5,11 Additional strengths include a comprehensive 
search strategy not limited to the English language and adherence to the PRISMA checklist. 
Limiting assessments of lung function, asthma symptoms, and safety of curcumin 
supplementation to randomized trials provided for more robust conclusions about the efficacy of 
curcumin supplementation.  
 
Limitations:                                                                                                                                    
Our review is limited by the number of studies available, small sample sizes of included 
studies, duration of follow up/length of treatment, inconsistencies in reporting of outcome 
measures, and risk of bias of included studies. Two studies additionally utilized mixed products 
and dosing strategies varied widely between 15mg – 2,200mg across studies.15,21 Additionally, 
findings are further limited by a lack of sufficient data assessing the impact of curcumin 
supplementation across a spectrum of asthma severities.  
 
Implications/Recommendations for research:                                                                                                            
We recommend future investigations to report on all lung functioning measures available 
through spirometry and to report asthma symptoms in an identical and consistent manner 
utilizing standardized asthma symptom questionnaires such as the ACT or AQLQ with total and 
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sub-scores readily available. Future studies should address concerns around the paucity of data 
available in children and adolescents as well as safety of curcumin supplementation. Although 
curcumin in doses as high as 12,000mg appear to be safe with no severe adverse effects, future 
studies should assess this in individuals being treated for asthma more specifically.29 
Additionally, studies should utilize similar doses, dosing strategies, and formulations of 
curcumin, examine the impact of curcumin across asthma severities, and improve upon the 
methodological quality currently available.  
Due to the hydrophobic and lipophilicity of curcumin, its bioavailability and absorption is 
notoriously low, known to degrade at physiological pH and rapidly metabolized, limiting its 
therapeutic effects.11,30 Chauhan et al., were able to demonstrate increased therapeutic efficacy, 
via intranasal administration in a murine model of asthma, finding a reduction in inflammatory 
signaling.31 However, additional research in humans is necessary to identify if intranasal 
applications provide any advantage over oral supplementation for individuals with asthma. 
 
Implications for clinical practice: 
Based on the results from our review, the use of curcumin to provide clinical benefit in 
asthma is likely minimal and recommending curcumin for asthma in clinical practice currently 
cannot be made and further high-quality research is necessary. Consistency in the reporting of 
lung functioning via spirometry as well as assessment of asthma symptoms are needed. It is still 
unclear at which dose/dosing strategy is most effective, how much benefit is provided to children 
or adolescents, if benefit is independent on asthma severity, and if benefits are sustained long 
term without significant adverse effects. If patients are utilizing curcumin supplementation with 
a perceived benefit, it is likely safe to continue supplementation as a dose escalation study of 
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curcumin was reported to be safe at an observed dosage of 12,000 mg in adults and adverse 
events were not associated with a dose dependent response.29 
 
Conclusions: 
This is the first systematic review with meta-analysis that study authors are aware of 
evaluating the efficacy of curcumin supplementation in humans with asthma. Limited evidence 
suggests short-term improvement in lung functioning assessed by spirometry with curcumin 
supplementation compared to control. Overall, asthma symptoms also seemed to improve, 
however, improvements in lung functioning and asthma symptoms need to be interpreted with 
caution due to the lack of adequate high-quality studies at low risk of bias. Recommendations for 
use in clinical practice cannot be made at this time and additional research with consistencies in 
outcome reporting, dosing, safety, length of follow up, and effects of curcumin supplementation 
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Table 1: Characteristics of studies assessing efficacy of curcumin supplementation for asthma in clinical trials 
Author, 
Year 








Egypt RCT n = 63 Non-smoking adults 
18-60 years old, 




controlled with low 
to moderate inhaled 
corticosteroids 
4-weeks Combination 
product taken 3 















need for rescue 
medication/wk; FVC%; 
FEV1%; PEFR; 
Frequency of acute 
exacerbations per wk, 
month, or year. 
Improvements in number of exacerbations/wk, 
daytime and nighttime symptoms/wk, need for rescue 
medication/wk, FVC. All p<0.001 compared to 
placebo. 
 
No statistically significant difference between groups 
for FEV1%, or PEFR.  
Kim et al. 
201125 
USA Double Blind 
RCT 
n = 15 Adults 18-60 years 
old with at least 1-
year of stable 
persistent asthma, 
FEV1 ≥ 60%, use of 
low to moderate 
inhaled 
corticosteroids, and 
allergic to dust 
mites.  
3 months Curcumin 
1,000mg twice 
daily (n=9) 
Placebo (n=6) Postbronchodilator 
FEV1; ACT scores; 
frequency of rescue 
inhaler use; dose of 
inhaled corticosteroids 
No statistically significant difference in any outcome 
between groups  
Abidi et 
al. 201426 
India Open label 
RCT 
n = 60 Non-smoking adults 
18-55 years old 











daily added on 







cough, chest tightness, 
nocturnal symptoms, 
total symptom score); 
pre-bronchodilator 
FEV1; post-
bronchodilator FEV1  
No statistically significant difference between groups 
in improvement of clinical symptoms. 
 
Curcumin improved FEV1 measures compared to 








N/A n = 100 Non-smokers with 
moderately 
controlled asthma 
on stable doses of 
inhaled 
glucocorticoids 
2 months Curcumin 
500mg twice 







FEV1%, ACT, AQLQ  
 
Curcumin improved FEV1% (p<0.001), 






n = 30 Non-smokers, at 
least 18 years old 














PEFR; length of 
hospital stay  
 
No statistically significant differences between groups 
in PEF improvement, or length of hospital stay.  
FEV1: Forced Expiratory Volume in 1 second; FEV1%: Predicted Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; PEFR: Peak Expiratory Flow Rate; ACT: 
Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; wk: week 
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Table 1 Continued 
Author, 
Year 












n = 150 Non-smoking adults 
at least 18 years old 
with moderate to 
severe asthma 
requiring moderate 
doses of inhaled 
glucocorticoids.   
3 months Curcumin 500mg 














FEV1%, ACT, AQLQ FEV1%, ACT and AQLQ improved in all groups. 
Statistically significant improvements in FEV1%, 
ACT, and AQLQ with curcumin compared to both 





n = 40 Chronic bronchial 
asthma  
2 months  Curcumin 750mg + 
Piperine 5mg twice 
daily added to 
standard of care (n = 
23) 
Standard of 





No statistically significant differences between 
groups for FEV1%, FEV1, or FEV1/FVC 
Manarin 
201922 
Brazil Double Blind 
RCT 
n = 34 Children and 
adolescents between 
7-18 years of age 
with persistent 
asthma  
6 months  Powdered Curcuma 







use of rescue inhaler; 
interference with 
normal activity; FEV1  
No difference between groups in frequency of 
symptoms, FEV1, or interference with normal 
activity. Curcumin improved frequency of 
nighttime awakenings (p<0.001), decreased 
frequency in use of rescue inhaler(p<0.0001), and 
overall disease control (p<0.01).   










Appendix 1: Search strategy  
PubMed: 
1. Asthma [MeSH] 
2. Asthma* [tw] 
3. Respiratory hypersensitivity [MeSH] 
4. Wheez* [tw] 
5. airway responsiveness [tw] 
6. airway hyperreactivity [tw] 
7. airway hyper-reactivity [tw] 
8. Airway hyper-responsiveness [tw] 
9. Bronchospasm [tw] 
10. bronchial responsiveness [tw] 
11. bronchial disorder [tw] 
12. bronchial hyperreactivity [tw]  
13. bronchial hyper-reactivity [tw] 
14. lung function [tw] 
15. ventilatory function [tw]  
16. Pulmonary function [tw]  
17. Respiratory function tests [MeSH] 
18. FEV [tw] 
19. FEF [tw] 
20. FVC [tw] 
21. PEF [tw] 
22. PTF [tw] 
23. Interluekin-4 [tw] 
24. Interleukin-5 [MeSH] 
25. IL-5 [tw] 
26. IL5 [tw] 
27. Interleukin-13 [MeSH] 
28. IL-13 [tw] 
29. IL13 [tw] 
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30. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR 
#17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 
31. Curcuma [MeSH] 
32. Curcumin [MeSH] 
33. Turmeric [tw] 
34. Tumeric [tw] 
35. Tetrahydrocurcumin [tw] 
36. Curcum* [tw] 
37. #31 OR #32 OR #33 OR #34 OR #35 OR #36 
38. #30 AND #37  
 
Google Scholar: 
All words: Curcuma and Asthma 
At least one word: Turmeric OR Curcuma OR Curcumin OR Lung Function OR Respiratory Hypersensitivity 
 
 





Section/topic  # Checklist item  
Reported on 
page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic 
review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and 
study design (PICOS).  
5  
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
6  
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication 
status) used as criteria for eligibility, giving rationale.  
 6-7 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the 
search and date last searched.  
8  
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Figure 1, 
Appendix 1  




Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
8  
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.  6-7  
Risk of bias in individual studies  12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or 
outcome level), and how this information is to be used in any data synthesis.  
 12 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  9  






Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting 
within studies).  
12  
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which 
were pre-specified.  
8-9  
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each 
stage, ideally with a flow diagram.  
Figure 1  
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
 11  
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Figure 2  
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention 
group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Figure 3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Figure 3 
12-13 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Figure 2 
12 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).  
15-16  
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
16-17  
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  18  
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
 19 
